Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia.
Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi-infarct dementia (MID) and primary degenerative dementia (PDD). Subjects were 34 MID patients and 39 PDD patients who met entrance criteria for the study. A repeated measures ANOVA showed significant improvement in both patients with MID and patients with PDD for word fluency. The total score on the Relatives' Assessment of Global Symptomatology-Elderly showed significant improvement for patients with PDD. The average score on the Instrumental Activities of Daily Living Scale, however, showed a significant decline for patients with PDD.
Dysken
M W
MW
Minneapolis Veterans Administration Medical Center, MN.
Katz
R
R
Stallone
F
F
Kuskowski
M
M
D000203:Activities of Daily Living / Q000523:psychology; D000368:Aged; D000369:Aged, 80 and over; D003704:Dementia / Q000188:drug therapy* / Q000523:psychology; D015161:Dementia, Multi-Infarct / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*
D011619:Psychotropic Drugs; D011759:Pyrrolidines; C040619:oxiracetam